Opinion|Videos|January 2, 2025
Exploring the Frontline Potential of Teclistamab: Insights From MajesTEC-5 at ASH 2024
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the MajesTEC-5 study, presented at ASH 2024, demonstrates the potential of teclistamab in combination with standard therapy in the frontline setting, highlighting its safety profile and 100% minimal residual disease (MRD) negativity after cycle 3, and explores how using bispecific antibodies like teclistamab earlier in treatment could influence future options for relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Bispecific antibodies have had a significant impact on the treatment landscape for R/R multiple myeloma. Data presented at ASH is evaluating the use of bispecifics earlier in treatment. Briefly describe the data presented on MajesTEC-5, which evaluates teclistamab in combination with standard therapy in the frontline setting.
- What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Primary end point: safety
- Secondary end point: MRD negativity, 100% after cycle 3
- How might using teclistamab in earlier lines of therapy influence treatment options in the relapsed setting?
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Sacituzumab Govitecan-hziy for First-Line Metastatic Triple-Negative Breast Cancer
2
CDC Officially Ends Hantavirus Response as Outbreak Risk Recedes
3
More Potent and Tolerable, Azenosertib Advances as the Leading WEE1 Inhibitor
4
CKD Caregiving Drives Social Isolation, Loneliness
5